SCHEMBL18930741

SCHEMBL18930741

N#Cc1ccc(C[C@@H](N)CNCCO)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
IDO1 P14902 2/20 0.37
MMP2 P08253 1/20 0.37
OPRK1 P41145 1/20 0.37
CYP2A6 P11509 1/20 0.37
FAP Q12884 2/20 0.36
DPP8 Q6V1X1 2/20 0.36
DPP9 Q86TI2 2/20 0.36
DPP7 Q9UHL4 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA9 Q16790 1/20 0.36
CTSC P53634 1/20 0.36
KCNH2 Q12809 1/20 0.36
SAE1 Q9UBE0 1/20 0.36
UBA2 Q9UBT2 1/20 0.36
TPH1 P17752 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21144815 0.98 DPP4 (0.41) DPP4LOXL2IDO1MMP2OPRK1
Hydrochloric Acid SCHEMBL21144818 0.98 DPP4 (0.41) DPP4LOXL2IDO1MMP2OPRK1
SCHEMBL18930595 0.80 LOXL2 (0.52) DPP4LOXL2IDO1CYP2A6FAP
SCHEMBL14860539 0.80 LOXL2 (0.52) DPP4LOXL2IDO1CYP2A6FAP
SCHEMBL20397577 0.80 LOXL2 (0.52) DPP4LOXL2IDO1CYP2A6FAP
SCHEMBL10904320 0.79 EPHX1 (0.55) MMP2OPRK1
SCHEMBL18930737 0.79 LOXL2 (0.47) DPP4LOXL2IDO1CYP2A6FAP
Hydrochloric Acid SCHEMBL18920607 0.79 LOXL2 (0.50) DPP4LOXL2IDO1CYP2A6FAP
SCHEMBL21144806 0.77 DPP4 (0.49) DPP4LOXL2MMP2FAPDPP8
SCHEMBL21144808 0.77 DPP4 (0.49) DPP4LOXL2MMP2FAPDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed
WO-2017093272-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 ATAD2, ATAD2B, TAF1L DPP4 3896/4885LOXL2 3917/4885IDO1 1704/4885
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 ATAD2, ATAD2B, TAF1L DPP4 3896/4885LOXL2 3917/4885IDO1 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.